Drug Trial Radar · NCT06959225
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
580
Actual
Start
Jun 23, 2025
Primary completion
Oct 29, 2026
Study completion Jul 11, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- May 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Conditions
- Hidradenitis Suppurativa
Interventions
Ruxolitinib CreamDrug
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Vehicle CreamDrug
Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who achieve Hidradenitis Suppurativa (HS) Clinical Response 75 (HiSCR75) from baselineTime frame: Week 16
Locations
101 sites in 8 countries. Site status is shown where the registry gives one.
Investigative Site US020
Phoenix, Arizona
Investigative Site US033
Scottsdale, Arizona
Investigative Site US054
Tempe, Arizona
Investigative Site US002
Fayetteville, Arkansas
Investigative Site US055
Brea, California
Investigative Site US004
Laguna Niguel, California
Investigative Site US007
Los Angeles, California
Investigative Site US013
San Diego, California
Investigative Site US060
San Diego, California
Investigative Site US038
San Diego, California
Investigative Site US059
Aurora, Colorado
Investigative Site US045
Boynton Beach, Florida
Investigative Site US028
Fort Myers, Florida
Investigative Site US016
Miami, Florida
Investigative Site US027
Sanford, Florida
Investigative Site US057
Sweetwater, Florida
Investigative Site US029
Tampa, Florida
Investigative Site US061
Atlanta, Georgia
Investigative Site US053
Atlanta, Georgia
Investigative Site US019
Marietta, Georgia
Investigative Site US026
Chicago, Illinois
Investigative Site US049
Clarksville, Indiana
Investigative Site US052
West Lafayette, Indiana
Investigative Site US001
Bowling Green, Kentucky
Investigative Site US022
Louisville, Kentucky
Investigative Site US050
Baton Rouge, Louisiana
Investigative Site US046
Glenn Dale, Maryland
Investigative Site US003
Boston, Massachusetts
Investigative Site US030
Boston, Massachusetts
Investigative Site US010
Quincy, Massachusetts
Investigative Site US051
Novi, Michigan
Investigative Site US006
Minneapolis, Minnesota
Investigative Site US021
New Brighton, Minnesota
Investigative Site US036
Saint Joseph, Missouri
Investigative Site US034
New City, New York
Investigative Site US018
New York, New York
Investigative Site US017
New York, New York
Investigative Site US023
Rochester, New York
Investigative Site US014
Chapel Hill, North Carolina
Investigative Site US025
Fargo, North Dakota
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.